My Profile

Search abstracts

Lewis Sheiner

Budapest, Hungary

Lisboa, Portugal

Hersonissos, Crete, Greece

Alicante, Spain

Glasgow, Scotland

Venice, Italy

Athens, Greece

Berlin, Germany

St. Petersburg, Russia

Marseille, France

KÝbenhavn, Denmark

Brugge/Bruges, Belgium

Pamplona, Spain

Uppsala, Sweden

Verona, Italy

Paris, France

Basel, Switzerland

Salamanca, Spain

Saintes, France

Wuppertal, Germany

Glasgow, Scotland

Sandwich, UK

Frankfurt, Germany

Greenford, UK

Paris, France

Basel, Switzerland

Printable version

Friday June 14
08:15-08:45 Registration and coffee
08:45-09:00 Welcome and Introduction
  Session I Free Communications Chair: Pascal Girard
09:00-09:20 Rudy Port Estimating individual pretreatment levels of a pharmacologic response variable
09:20-09:40 Willi Weber Leflunomide population pharmacokinetics and its interaction with activated charcoal/cholestyramine
09:40-10:00 M. Audran A population pharmacodynamics model of recombinant human erythropoietin in athletes
10:00-10:20 Michel Tod Comparison of ED, EID, API and Bayesian-API criteria for the robust optimization of sampling times in pharmacokinetics
10:20-11:00 Coffee Break, Poster Session I, Software Demonstrations
  Session II Drug Development Chair: René Bruno
11:00-11:30 Eliane Fuseau Population pharmacokinetics - an industrial viewpoint
11:30-12:00 Janet Wade Presentation Of Population Analyses For Regulatory Submissions
12:00-12:20 Mats Karlsson A population PK/PD model for the anti-Parkinsonian triple therapy: levodopa (LD), dopadecarboxylase (DDC) inhibitor and catechol-O-methyl transferase (COMT) inhibitor
12:20-13:40 Lunch
  Session III Software I Chair: Ferdie Rombout
13:40-14:10 Stuart Beal A preview of NONMEM version V
14:10-14:15 Alison Thomson Short introduction to data set
14:15-14:35 Niclas Jonsson Xpose
14:35-15:05 Roberto Gomeni Visual NM
15:05-15:50 Coffee break, Poster Session II, Software Demonstration
  Session IV Software II Chair: Alain Mallet
15:50-16:20 Guenther Strehlau POPKAN
16:20-16:50 Pascal Girard P-Pharm
20:00-24:00 Social Evening  
Saturday June 15
  Session V Methodology Chair: Jean-Louis Steimer
09:00-09:45 Stuart Beal Simulating PK/PD trials
09:45-10:30 France Mentré Optimal design in population pharmacokinetics
10:30-11:15 Coffee break, Poster Session III, Software Demonstration
  Session VI Methodology/Clinical Applications Chair: Willi Weber
11:15-11:45 Pascal Girard A population markov model for analyzing dose history
11:45-12:15 Pascal Maire Individualized Drug Therapy and Population Modeling
12:15-12:35 Christian Pobel Neural network prediction of dose and pk parameters values from a population approach point of view
12:35-12:55 Farkad Ezzet Inter-occasion variation in the bioavailability of Benflumetol (an anti malarial drug)
12:55 Closing Statements


- D. de Alwis, L. Aarons
The population pharmacokinetics of ondansetron: a covariate analysis
- F. Mentre, E. Comets, F. Pousset, B. Plaud, B. Diquet, G. Montalescot, A. Ankri, A. Mallet, Ph. Lechat
Population pharmacokinetics/pharmacodynamics of fluindione in patients
- D. Santos Buelga, M.J. Garcia Sanchez, A.C. Falcao, M.E. Mendez, A. Dominguez-Gil.
Population pharmacokinetics of tobramycin in neonates
- C. Pobel, D. Breilii, M.C. Saux, S. Demare, J.N. Parola
A population pharmacokinetic study of ciprofloxacine penetration into lung tissue
- M.L. McFadyen, M.P. Majola, R. Nair, M. Govender, H. Laher
The relationship of phenytoin concentrations to gingival hyperplasia
- Z. Hussein, C.J. Eaves, D.B. Hutchinson, C.J. Canfield
Population pharmacokinetics of proguanil in patients with acute P. falciparum malaria after combined therapy with atovaquone

- R.C. Schoemaker, J. Burggraaf, A.F. Cohen
Assessment of liver blood flow using a continuous infusion of a drug with high hepatic clearance
- C. Laveille, F. Le coz, G. Lerebours, G. Resplandy, R. Jochemsen
Population pharmacokinetics of a new bradycardic agent in healthy male volunteers: influence of food and time of administration
- V. Piotrovskij, E. Snoek, A. van Peer
Liarozole population pharmacokinetics at the steady state
- T. Bouillon, D. Kietzmann, I. Meineke, R. Port, A. Hoeft
Pharmacokinetics of piritramide in patients undergoing elective surgery
- P.Milligan, M.Karlsson, D.Nichols
Experiences with CYP2D6 polymorphism in clinical drug development
- H. Schmid, G. Strehlau
Probability Statements about predicted kinetic/dynamic profiles in population analyses

- F. Ezzet
Population pharmacokinetics of Valsartan
- N.J. Bruce, A.H. Thomson, N. Undre, P. Stadler, H.L. Elliott
Assesment of Covariate Relationships in the Analysis of the Population Pharmacokinetics of Tacrolimus.
- M. Gardmark, M.O. Karlsson, M. Hammarlund-Udenaes
A pharmacodynamic model for morphine incorporating acute tolerance and M3G interactions
- L. Nguyen, G. Bastian, F. Doz, S. Urien, B. Peng, E. Chatelut, A.V. Boddy, D.R. Newell, H. Rubie, G. Houin, P. Canal
Prospective evaluation of a formula to predict carboplatin clearance in children
- S. Urien
MP2 (V2.0) A Windows application for population pharmacokinetics
- N.J. Rahman, J.C. Wakefield, C. Falcoz
Incorporation of population pharmacokinetic principles into drug development